Computational modeling of selected phytochemicals from Reevesia formosana: mechanistic insights into their potential against lung cancer
Abstract
Background: Lung cancer remains a dominant cause of cancer mortality, and impaired apoptosis mediated by anti-apoptotic Bcl-2 family proteins contributes to persistence and treatment resistance. Phytochemicals from Reevesia formosana display reported anti-NSCLC (Non-Small Cell Lung Cancer) activity, yet target-level mechanisms remain incompletely defined.
Objectives: To prioritize Reevesia formosana phytochemicals as putative Bcl-2 (PDB ID: 6GL8) inhibitors and to derive mechanistic insight through multiscale computation.
Materials and methods: Six phytochemicals and the reference Tivantinib were docked to 6GL8, and the top candidate (CPD1) was evaluated by 100 ns molecular dynamics simulations alongside Tivantinib. MMGBSA binding free energies were computed from 125 snapshots spanning 20-100 ns. ADMET properties were predicted using pkCSM. Frontier-orbital and global reactivity descriptors were obtained by DFT.
Results: Docking ranked CPD1 highest (-10.15 kcal/mol) relative to Tivantinib (-8.83 kcal/mol), with hydrogen bonding to Tyr108 and Arg129 and extensive pocket complementarity. MD trajectories indicated a more confined CPD1-6GL8 complex (RMSD mainly 0.18–0.22 nm) than Tivantinib-6GL8 (0.21–0.26 nm, occasional 0.27-0.28 nm), with comparable compactness (Rg of 1.44 nm) and bounded SASA. Hydrogen-bond counts supported intermittent polar anchoring for CPD1 (0-3) and higher early sampling for Tivantinib. MMGBSA favored CPD1 (ΔTOTAL -32.87 ± 4.28 kcal/mol) over Tivantinib (-17.27 ± 2.81 kcal/mol), supported by stronger ΔVDWAALS (-40.76 vs -31.34 kcal/mol) and a smaller ΔG_SOLV (20.28 vs 24.14 kcal/mol). ADMET prediction indicated high intestinal absorption with limited solubility, restricted BBB/CNS permeability, fewer CYP inhibition flags, and no hepatotoxicity alert for CPD1, while hERG II inhibition was flagged for both ligands. DFT showed similar EHOMO (eV) but a narrower ΔE (eV) and higher ω (eV) for CPD1 than for Tivantinib.
Conclusions: Integrated modeling prioritizes CPD1 as a Bcl-2-targeting scaffold for lung cancer-relevant studies, supporting structure-guided optimization and experimental verification.
Downloads
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834
Zou K, Sun P, Huang H, Zhuo H, Qie R, Xie Y, et al. Etiology of lung cancer: Evidence from epidemiologic studies. J Natl Cancer Cent. 2022;2(4):216–25. https://doi.org/10.1016/j.jncc.2022.09.004
Relli V, Trerotola M, Guerra E, Alberti S. Abandoning the notion of non-small cell lung cancer. Trends Mol Med. 2019;25(7):585–94. https://doi.org/10.1016/j.molmed.2019.04.012
Jiang S-X, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol. 1995;177(2):135–8. https://doi.org/10.1002/path.1711770206
Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022;12:985363. https://doi.org/10.3389/fonc.2022.985363
Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M, et al. Apoptosis: A comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. Cells 2024;13(22):1838. https://doi.org/10.3390/cells13221838
Montero J, Haq R. Adapted to survive: Targeting cancer cells with BH3 mimetics. Cancer Discov. 2022;12(5):1217–32. https://doi.org/10.1158/2159-8290.CD-21-1334
Hassig CA, Zeng F-Y, Kung P, Kiankarimi M, Kim S, Diaz PW, et al. Ultra-high-throughput screening of natural product extracts to identify proapoptotic inhibitors of Bcl-2 family proteins. SLAS Discov. 2014;19(8):1201–11. https://doi.org/10.1177/1087057114536227
Shah U, Shah R, Acharya S, Acharya N. Novel anticancer agents from plant sources. Chin J Nat Med. 2013;11(1):16–23. https://doi.org/10.1016/S1875-5364(13)60002-3
Chihomvu P, Ganesan A, Gibbons S, Woollard K, Hayes MA. Phytochemicals in drug discovery-A confluence of tradition and innovation. Int J Mol Sci. 2024;25(16):8792. https://doi.org/10.3390/ijms25168792
Yang Y, Wang H, Xue Q, Peng W, Zhou Q. New advances of natural products in non-small cell lung cancer: From mechanisms to therapies. J Ethnopharmacol. 2025;346:119636. https://doi.org/10.1016/j.jep.2025.119636
Wei J, Yan Y, Chen X, Qian L, Zeng S, Li Z, et al. The roles of plant-derived triptolide on non-small cell lung cancer. Oncol Res. 2019;27(7):849-58. https://doi.org/10.3727/096504018X15447833065047
Othman ZK, Ahmed MM, Kasimieh O, Musa SS, Branda F, Cue EG, et al. Artificial intelligence for natural product drug discovery and development: current landscape, applications, and future directions. Intell Med. 2025;12:100316. https://doi.org/10.1016/j.ibmed.2025.100316
Hsiao PY, Lee SJ, Chen IS, Hsu HY, Chang HS. Cytotoxic cardenolides and sesquiterpenoids from the fruits of Reevesia formosana. Phytochemistry. 2016;130:282-90. https://doi.org/10.1016/j.phytochem.2016.06.009
Casara P, Davidson J, Claperon A, Toumelin-Braizat G Le, Vogler M, Bruno A, et al. S55746 is a novel orally active BCL2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 2018;9(28):20075–88. https://doi.org/10.18632/oncotarget.24744
Nguyen HD. DFT and molecular modelling reveal the mechanism of action of selected alkaloids as anti-colorectal cancer agents targeting topoisomerase II. Not Sci Biol. 2025;17(3):12642. https://doi.org/10.55779/nsb17312642
Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: Fast, flexible, and free. J Comput Chem. 2005;26(16):1701–18. https://doi.org/10.1002/jcc.20291
Zoete V, Cuendet MA, Grosdidier A, Michielin O. SwissParam: A fast force field generation tool for small organic molecules. J Comput Chem. 2011;32(11):2359–68. https://doi.org/10.1002/jcc.21816
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera–A visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12. https://doi.org/10.1002/jcc.20084
Nguyen HD. Unveiling the anti-apoptotic mechanism of magnolialide as a colorectal cancer inhibitor via molecular modeling, ADMET, and MMGBSA analysis. Phys Chem Res. 2025;13(4):783–96. https://doi.org/10.22036/pcr.2025.535946.2708
Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066–72. https://doi.org/10.1021/acs.jmedchem.5b00104
Neese F. Software update: The ORCA program system–version 6.0. Wiley Interdiscip Rev Comput Mol Sci. 2025;15(2):e70019. https://doi.org/10.1002/wcms.70019
Knizia G, Klein JE. Electron flow in reaction mechanisms–revealed from first principles. Angew Chem Int Ed. 2015;54(18):5518–22. https://doi.org/10.1002/anie.201410637
Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform. 2012;4(1):17. https://doi.org/10.1186/1758-2946-4-17
Luo J, Xue ZQ, Liu WM, Wu JL, Yang ZQ. Koopmans’ theorem for large molecular systems within density functional theory. J Phys Chem. A. 2006;110(43):12005–9. https://doi.org/10.1021/jp063669m
Das R, Vigneresse J-L, Chattaraj PK. Chemical reactivity through structure-stability landscape. Int J Quantum Chem. 2014;114(21):1421–9. https://doi.org/10.1002/qua.24706
Bell EW, Zhang Y. DockRMSD: An open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism. J Cheminform. 2019;11(1):40. https://doi.org/10.1186/s13321-019-0362-7
Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. Neuron 2018;99(6):1129-43. https://doi.org/10.1016/j.neuron.2018.08.011
Zhao S, Ma S, Zhang Y, Gao M, Luo Z, Cai S. Combining molecular docking and molecular dynamics simulation to discover four novel umami peptides from tuna skeletal myosin with sensory evaluation validation. Food Chem. 2024;433:137331. https://doi.org/10.1016/j.foodchem.2023.137331
Salmaso V, Moro S. Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. Front Pharmacol. 2018;9:923. https://doi.org/10.3389/fphar.2018.00923
Hosseini M, Fattahi A, Pakzadiyan A. Computational and experimental design of L-amino acid-based alternatives to ketorolac. Sci Rep. 2025;15(1):42161. https://doi.org/10.1038/s41598-025-26171-1
Schiffmann C, Sebastiani D. Hydrogen bond networks: Structure and dynamics via first-principles spectroscopy. Phys Status Solidi B. 2012;249(2):368–75. https://doi.org/10.1002/pssb.201100556
Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, et al. End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chem Rev. 2019;119(16):9478–508. https://doi.org/10.1021/acs.chemrev.9b00055
Ferreira LLG, Andricopulo AD. ADMET modeling approaches in drug discovery. Drug Discov Today. 2019;24(5):1157–65. https://doi.org/10.1016/j.drudis.2019.03.015
Chandrasekaran B, Abed SN, Al-Attraqchi O, Kuche K, Tekade RK. Computer-aided prediction of pharmacokinetic (ADMET) properties. In: Tekade RK, editor. Dosage Form Design Parameters. Volume II. Oxford: Academic Press; 2018 p. 731–55. https://doi.org/10.1016/B978-0-12-814421-3.00021-X
Nguyen HD. DFT and molecular modelling reveal the mechanism of action of selected alkaloids as anti-colorectal cancer agents targeting topoisomerase II. Not Sci Biol. 2025;17(3):12642. https://doi.org/10.55779/nsb17312642
Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;22(23):12808. https://doi.org/10.3390/ijms222312808
Copyright (c) 2026 Hung Duc Nguyen
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
